Breast Cancer Clinical Trial
Official title:
Resource-sparing Radiotherapy for Breast Cancer
This study compares two different field set-ups in patients with breast cancer following a
breast resection (mastectomy). These two set-ups are as follows: arm a - radiotherapy to the
chest-wall only, and arm b - radiotherapy to the chest-wall and the supraclavicular fossa.
Patients in both treatment arms will receive radiotherapy with a shortened fractionation
schedule.
Study hypothesis: irradiation of the chest-wall only is not inferior to irradiation of the
chest-wall and supraclavicular fossa in terms of loco-regional control, survival and
treatment toxicity.
Post-mastectomy radiotherapy (PMRT) substantially reduces the risk of loco- regional failure
as shown in several studies and meta-analyses. Two large trials for pre-menopausal
node-positive breast cancer patients treated with mastectomy and chemotherapy showed that
PMRT not only reduced loco- regional failure rates but also improved disease-free and
overall survival rates.
Although the benefit of PMRT is clear, the optimal volume of tissues to be covered by the
radiotherapy fields is controversial. Since the chest wall is the most likely location of
recurrence, there is uniform consensus that the chest wall should be irradiated. However,
areas of controversy exist regarding irradiation of the regional lymph nodes (axillary,
supraclavicular and internal mammary lymph nodes), optimal radiation dose, and
dose-fractionation.
If equivalent results could be achieved by omitting irradiation of the supraclavicular
region in patients receiving adjuvant systemic therapy, this will simplify and expedite
treatment in this patient population. Furthermore, the use of a shortened fractionation
schedule of 40 Gy in 15 fractions (2.67 Gy per fraction) over 3 weeks which has been used in
the UK and Canada for post-mastectomy patients for several decades will shorten the duration
of treatment by reducing the number of patient visits for radiotherapy and increase the
number of patients who can be treated. Treatment will be more convenient for patients and a
reduction in the number of treatments could result in savings for strained health care
systems.
This is a randomized comparison of two different radiotherapy field set-ups for
post-mastectomy treatment of locally advanced breast cancer. Patients who have undergone
modified radical mastectomy including axillary lymph node dissection will be randomized to
receive one of two radiotherapy treatment arms, A and B following the completion of adjuvant
chemotherapy. The radiotherapy for treatment Arm A consists of irradiation of the chest wall
only while Treatment Arm B includes irradiation of the chest wall and the ipsilateral
supraclavicular field. Patients on both treatment arms will receive radiation with a
shortened fractionation schedule. Patients will be evaluated for local control, regional
control, survival and treatment toxicity.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |